Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1030
- Registration Number
- NCT00982644
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 629
- Registration Number
- NCT00982228
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12
- Registration Number
- NCT00976326
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1006
- Registration Number
- NCT00972283
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Mersin, Turkey
Comparison of Two NN1250 Formulations in Healthy Volunteers
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00966368
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Chula Vista, California, United States
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT00964964
A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00964418
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT00961324
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT00841087
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 245
- Registration Number
- NCT00611884
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.